Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Genus (GNS) Share Price

Price 3,055.00p on 30-01-2026 at 06:00:05
Change 0.00p 0%
Buy 0.00p
Sell 0.00p
Last Trade: Sell 375.00 at 3,017.1867p
Day's Volume: 0
Last Close: 3,055.00p
Open: 0.00p
ISIN: GB0002074580
Day's Range 0.00p - 0.00p
52wk Range: 1,548.00p - 3,220.00p
Market Capitalisation: £2.03b
VWAP: 0.00p
Shares in Issue: 66.41m

Genus (GNS) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 375 3,017.1867p Ordinary
16:45:21 - 29-Jan-26
Buy* 6,386 3,055.00p SI Trade
16:36:27 - 29-Jan-26
Buy* 6,386 3,055.00p SI Trade
16:36:27 - 29-Jan-26
Buy* 13 3,055.00p SI Trade
16:35:24 - 29-Jan-26
Buy* 1,001 3,055.00p SI Trade
16:35:24 - 29-Jan-26
Buy* 189 3,055.00p SI Trade
16:35:24 - 29-Jan-26
Buy* 41,581 3,055.00p Suspected BUY Trade
16:35:24 - 29-Jan-26
Buy* 3 3,035.00p Automatic Execution
16:29:57 - 29-Jan-26
Buy* 3 3,035.00p Automatic Execution
16:29:00 - 29-Jan-26
Sell* 129 3,030.00p Automatic Execution
16:29:00 - 29-Jan-26
See more Genus trades

Genus (GNS) Share Price History

Time period:
to
Date Open High Low Close Volume
30th Jan 2026 (Fri) 3,055.00 3,055.00 3,055.00 3,055.00 0
29th Jan 2026 (Thu) 3,020.00 3,055.00 2,990.00 3,055.00 191,740
28th Jan 2026 (Wed) 2,955.00 3,035.00 2,955.00 3,035.00 234,274
27th Jan 2026 (Tue) 2,900.00 2,985.00 2,875.00 2,970.00 354,288
26th Jan 2026 (Mon) 2,845.00 2,905.00 2,805.00 2,895.00 443,325
23rd Jan 2026 (Fri) 2,865.00 2,865.00 2,765.00 2,815.00 52,804
22nd Jan 2026 (Thu) 2,830.00 2,850.00 2,775.00 2,800.00 73,926
21st Jan 2026 (Wed) 2,780.00 2,805.00 2,700.00 2,800.00 59,852
20th Jan 2026 (Tue) 2,795.00 2,795.00 2,740.00 2,765.00 54,184
19th Jan 2026 (Mon) 2,800.00 2,900.00 2,800.00 2,835.00 123,016
16th Jan 2026 (Fri) 3,020.00 3,035.00 2,745.00 2,835.00 330,027
15th Jan 2026 (Thu) 2,585.00 2,630.00 2,555.00 2,630.00 184,378
14th Jan 2026 (Wed) 2,520.00 2,610.00 2,500.00 2,595.00 359,349
13th Jan 2026 (Tue) 2,560.00 2,570.00 2,510.00 2,515.00 62,724
12th Jan 2026 (Mon) 2,495.00 2,580.00 2,495.00 2,565.00 1,517,207
9th Jan 2026 (Fri) 2,570.00 2,570.00 2,535.00 2,540.00 77,835
8th Jan 2026 (Thu) 2,615.00 2,635.00 2,545.00 2,565.00 243,059
7th Jan 2026 (Wed) 2,610.00 2,655.00 2,580.00 2,635.00 74,546
6th Jan 2026 (Tue) 2,575.00 2,575.00 2,490.00 2,575.00 68,726
5th Jan 2026 (Mon) 2,565.00 2,580.00 2,515.00 2,525.00 74,199
2nd Jan 2026 (Fri) 2,605.00 2,610.00 2,545.00 2,545.00 29,338
1st Jan 2026 (Thu) 2,595.00 2,595.00 2,595.00 2,595.00 0
31st Dec 2025 (Wed) 2,650.00 2,650.00 2,585.00 2,595.00 14,545
30th Dec 2025 (Tue) 2,590.00 2,620.00 2,565.00 2,615.00 31,771
See more Genus price history

Genus (GNS) Regulatory News

Date Source Headline
23rd Jan 2026 5:23 pm RNS PRP Regulatory Progress – Canada
16th Jan 2026 7:00 am RNS Half Year Trading Update – Ahead of expectations
27th Nov 2025 7:00 am RNS Director/PDMR Shareholding
19th Nov 2025 12:12 pm RNS Results of AGM
19th Nov 2025 7:00 am RNS Non-Executive Director Appointments
19th Nov 2025 7:00 am RNS AGM Trading Update
3rd Nov 2025 10:56 am RNS Total Voting Rights
14th Oct 2025 4:02 pm RNS Notification of Major Holdings
10th Oct 2025 7:00 am RNS Notice of AGM
1st Oct 2025 9:47 am RNS Total Voting Rights
See more Genus regulatory news

Genus (GNS) Share News

LONDON BRIEFING: GSK wins EU nod for RSV shot; Spire in early talks

26th Jan 2026 07:59

(Alliance News) - GSK wins EU approval to expand use of its RSV vaccine Arexvy to all adults over 18, while Grainger unveils plans for a 195-home West London development, and Impax Environmental Markets outlines its tender offer plan amid continued pressure from activist investor Saba. Read More

IN BRIEF: Genus says PRRS resistant pig gene edit approved in Canada

26th Jan 2026 06:57

Genus PLC - Basingstoke, England-based animal biotechnology and genetics - Says government approves the use of its gene edit for pigs, which provides resistance to a global disease. Porcine reproductive and respiratory syndrome causes suffering and premature death to pigs, with Genus noting a study that estimated the cost of PRRS at USD1.2 billion per year in the US alone. The approval of the PRRS resistant pig programme follows years of work with multiple Canadian regulators, Genus says, and is an important step toward commercialisation in North America. Genus is seeking approval for the PRP gene edit in key North American export markets such as Mexico and Japan, as well as in China. Read More

LONDON BROKER RATINGS: Goldman Sachs ups targets for Schroders, LSEG

19th Jan 2026 09:45

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More

LONDON MARKET CLOSE: Miners hold FTSE 100 back in sluggish end to week

16th Jan 2026 17:09

(Alliance News) - Stocks in London ended little changed on Friday, with blue chips edging lower after notching another record, as investors held fire ahead of the long weekend in the US. Read More

LONDON BROKER RATINGS: BofA cuts British Land; RBC raises Gym Group

16th Jan 2026 09:48

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More

See more Genus news
FTSE 100 Latest
Value10,171.76
Change17.33

Login to your account

Forgot Password?

Not Registered